Oncology, Rare Disease Drugs Dominate New China Approvals
Mix Of Nods For Foreign, Local Firms
Rare disease and cancer treatments are front and center in the latest batch of China new drug approvals, while a new biosimilar of a big seller moves into the spotlight.
